MedTrace Logo

To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital

NCT07337434 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2026-01-13

No results posted yet for this study

Summary

This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.

Conditions

  • Chronic Plaque Psoriasis

Interventions

DRUG

Methotrexate

Group A will recieve methotrexate 10-25mg once weekly for 3 months. Along with folic acid once daily except on day of methotrexate.

DRUG

Apremilast

Group B will recieve tablet apremilast 30mg twice daily for 3 months.

Sponsors & Collaborators

  • Syeda Sana Zaman

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-25
Primary Completion
2026-06-25
Completion
2026-06-25

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07337434 on ClinicalTrials.gov